Immunotherapy for bladder cancer. Is the black box becoming grayer?

All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors.

The Journal of urology·2022

Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes.

European urology oncology·2021

Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design.

The Journal of urology·2021

The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.

BJU international·2020

Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?

European urology oncology·2019

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

European urology oncology·2019

Post-Diagnostic Red Meat, Poultry, and Egg Intake and Risk of Prostate Cancer Progression and Mortality: A Systematic Review.

The Journal of urology·2026

Second Time's a Charm? A Matched Case-Control Analysis of Revision Urethroplasty versus Primary Urethroplasty.

The Journal of urology·2026

Delineating the Long-Term Incidence of Urethral Complications After Prostate Cancer Treatment: A Population-Based Analysis.

The Journal of urology·2026

Anakinra Prophylaxis for Recurrent Severe ICANS Associated With Tarlatamab in Small Cell Lung Cancer: Case Report.

JTO clinical and research reports·2026

Prognostic value of CD103+ tumor-infiltrating lymphocytes in bladder cancer: A systematic review and meta-analysis.

Urologic oncology·2026

Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026

B-cells in breast cancer: current insights and challenges.

Frontiers in oncology·2026

Tumor immunosenescence drives breast cancer progression and therapeutic resistance: mechanisms and emerging interventions.

Frontiers in oncology·2026

The heterogeneous and dynamic immune-tumor interface in breast cancer.

Frontiers in oncology·2026

Related Experiment Videos

Immunotherapy for bladder cancer. Is the black box becoming grayer?

Related Concept Videos

All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors.

Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes.

Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design.

The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.

Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

Post-Diagnostic Red Meat, Poultry, and Egg Intake and Risk of Prostate Cancer Progression and Mortality: A Systematic Review.

Second Time's a Charm? A Matched Case-Control Analysis of Revision Urethroplasty versus Primary Urethroplasty.

Delineating the Long-Term Incidence of Urethral Complications After Prostate Cancer Treatment: A Population-Based Analysis.

Anakinra Prophylaxis for Recurrent Severe ICANS Associated With Tarlatamab in Small Cell Lung Cancer: Case Report.

Prognostic value of CD103+ tumor-infiltrating lymphocytes in bladder cancer: A systematic review and meta-analysis.

Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.

B-cells in breast cancer: current insights and challenges.

Tumor immunosenescence drives breast cancer progression and therapeutic resistance: mechanisms and emerging interventions.

The heterogeneous and dynamic immune-tumor interface in breast cancer.

Related Experiment Videos

Immunotherapy for bladder cancer. Is the black box becoming grayer?

Related Concept Videos

Related Articles